A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)

PURPOSE: A phase I clinical study was conducted to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan hydrochloride (CPT-11) in CPT-11/pegylated liposomal doxorubicin (PLD) combination therapy, a novel treatment regimen for platinum- and taxane-resistant recurrent...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Tadahiro, Takatori, Eriko, Kaido, Yoshitaka, Omi, Hideo, Yokoyama, Yoshihito, Mizunuma, Hideki, Kaiho, Michiko, Otsuki, Takeo, Takano, Tadao, Yaegashi, Nobuo, Nishiyama, Hiroshi, Fujimori, Keiya, Sugiyama, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000409/
https://www.ncbi.nlm.nih.gov/pubmed/24585045
http://dx.doi.org/10.1007/s00280-014-2418-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000409/
https://www.ncbi.nlm.nih.gov/pubmed/24585045
http://dx.doi.org/10.1007/s00280-014-2418-8

Ejemplares similares